Department of Psychiatry and Behavioral Sciences, University of California, Davis, Medical Center, Sacramento, CA, USA.
Menopause. 2010 Mar;17(2):410-5. doi: 10.1097/gme.0b013e3181bf5a62.
OBJECTIVE: The aim of this study was to examine the association of vasomotor symptoms (VMS) with anxiety and/or depressive symptoms in perimenopausal women. METHODS: A retrospective chart review of 487 women 40 to 64 years old seen during October 2004 to December 2006 in the Women's Midlife Assessment Program at the University of California, Davis, was performed. Of these, 395 women were included in the analysis: 58 (15%) were premenopausal, 199 (50%) were perimenopausal, and 138 (35%) were postmenopausal. VMS bothersomeness was represented by converting Likert-scale ratings for hot flashes and night sweats to scores and adding them into an overall score. Multiple logistic regression models were used to quantify the association of self-reported anxiety and/or depressive symptoms with VMS bothersomeness. RESULTS: Thirty-one (53%) premenopausal, 131 (66%) perimenopausal, and 69 (50%) postmenopausal women reported anxiety and/or depressive symptoms. Perimenopausal and postmenopausal women reporting anxiety and/or depressive symptoms had significantly higher VMS bothersomeness scores (2.2 +/- 1.7 and 2.2 +/- 1.9, respectively) than did women who did not report these symptoms (1.7 +/- 1.7 and 1.6 +/- 1.7, respectively; both P values < 0.05). Women experiencing more bothersome VMS were significantly more likely to report anxiety and/or depressive symptoms (odds ratio, 1.5; P < 0.01). Perimenopausal women were significantly more likely to report anxiety and/or depressive symptoms than were postmenopausal women (odds ratio, 1.9; P < 0.01). Both associations remained significant after restricting the analyses to women not taking hormone therapy or psychotropics. CONCLUSIONS: VMS bothersomeness was associated with self-reported anxiety and/or depressive symptoms, showing the importance of screening for anxiety and mood changes during perimenopause.
目的:本研究旨在探讨绝经前妇女血管舒缩症状(VMS)与焦虑和/或抑郁症状的关系。
方法:对 2004 年 10 月至 2006 年 12 月期间在加利福尼亚大学戴维斯分校妇女中年评估计划中就诊的 487 名 40 至 64 岁女性进行了回顾性图表审查。其中,395 名女性纳入分析:58 名(15%)为绝经前,199 名(50%)为围绝经期,138 名(35%)为绝经后。通过将潮热和盗汗的李克特量表评分转换为分数并将其添加到总分中,来表示 VMS 的困扰程度。采用多元逻辑回归模型来量化自述焦虑和/或抑郁症状与 VMS 困扰程度的关联。
结果:31 名(53%)绝经前、131 名(66%)围绝经期和 69 名(50%)绝经后女性报告有焦虑和/或抑郁症状。报告有焦虑和/或抑郁症状的围绝经期和绝经后女性 VMS 困扰评分明显更高(分别为 2.2 +/- 1.7 和 2.2 +/- 1.9,P 值均<0.05),而未报告这些症状的女性评分分别为 1.7 +/- 1.7 和 1.6 +/- 1.7(均 P 值<0.05)。VMS 困扰程度较高的女性报告焦虑和/或抑郁症状的可能性显著更高(优势比,1.5;P<0.01)。与绝经后女性相比,围绝经期女性报告焦虑和/或抑郁症状的可能性显著更高(优势比,1.9;P<0.01)。在限制仅分析未服用激素治疗或精神药物的女性后,这两种关联仍然具有统计学意义。
结论:VMS 的困扰程度与自述的焦虑和/或抑郁症状相关,表明在围绝经期期间筛查焦虑和情绪变化的重要性。
Maturitas. 2006-9-20
Menopause. 1999
Post Reprod Health. 2023-12
Womens Midlife Health. 2022-5-5
Braz J Psychiatry. 2021
Womens Midlife Health. 2020-10-6
Eur J Microbiol Immunol (Bp). 2016-1-27
Curr Psychiatry Rep. 2015-12